Chiang CL-L, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki BJ, et al. Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One. 2011;6(12):e28732.

CAS  Article  Google Scholar 

Njue A, Colosia A, Trask PC, Olivares R, Khan S, Abbe A, et al. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2015;15(1):1-12. e7.

Article  Google Scholar 

Wei F-Q, Sun W, Wong T-S, Gao W, Wen Y-H, Wei J-W, et al. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. J Exp Clin Cancer Res. 2016;35(1):1–9.

Article  Google Scholar 

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62–71.

CAS  Article  Google Scholar 

Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4):857–77.

CAS  Article  Google Scholar 

Aalipour A, Advani RH. Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol. 2014;5(4):121–33.

CAS  Article  Google Scholar 

de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, et al. FDA approval: Ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586–90.

Article  Google Scholar 

Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Nishikawa T. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. J Clin Exp Hematop. 2019;59(2):98–100.

Article  Google Scholar 

Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45.

CAS  Article  Google Scholar 

Kolibaba K, Burke JM, Brooks HD, Mahadevan D, Melear J, Farber CM, et al. Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial. Blood. 2015;126(23):3980.

Article  Google Scholar 

Jerkeman M, Hutchings M, Räty R, Wader KF, Laurell A, Christensen JH, et al. Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. Blood. 2020;136:36–36.

Google Scholar 

Jain P, Zhao S. Ibrutinib with Rituximab in first-line treatment of older patients with mantle cell lymphoma. J Clin Oncol. 2022;40(2):202–12.

CAS  Article  Google Scholar 

Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018;182(3):404-11.

CAS  Article  Google Scholar 

Handunnetti SM, Anderson MA, Burbury K, Hicks RJ, Birbirsa B, Bressel M, et al. Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study. Blood. 2019;13:134:756.

Bond DA, Alinari L, Maddocks K. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions. Clin Adv Hematol Oncol. 2019;17(4):223–33.

PubMed  Google Scholar 

Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233–40.

CAS  Article  Google Scholar 

Bond DA, Maddocks KJ. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020;34(5):903–21.

Article  Google Scholar 

Kim ES, Dhillon S. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015;75(7):769–76.

CAS  Article  Google Scholar 

Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol. 2015;6(5):242–52.

CAS  Article  Google Scholar 

McDermott J, Jimeno A. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. Drugs Today (Barcelona, Spain : 1998). 2014;50(4):291–300.

CAS  Article  Google Scholar 

Hanna KS, Campbell M, Husak A, Sturm S. The role of Bruton’s tyrosine kinase inhibitors in the management of mantle cell lymphoma. J Oncol Pharm Pract. 2020;26(5):1190–9.

CAS  Article  Google Scholar 

Tucker DL, Rule SA. Ibrutinib for mantle cell lymphoma. Future Oncol. 2016;12(4):477–91.

CAS  Article  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

Article  Google Scholar 

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2019.

Book  Google Scholar 

Wang M, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, et al. Efficacy and safety of single-agent Ibrutinib in patients with mantle cell lymphoma who progressed after Bortezomib therapy. Blood. 2014;124(21):4471.

Article  Google Scholar 

Wang M, Jain P, Yao Y, Liu Y, Zhao S, Hill H, et al. Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. Blood. 2020;136(Supplement 1):35–6.

Article  Google Scholar 

Giné E, de la Cruz F, Ubieto AJ, Jimenez JL, García-Sancho AM, Terol MJ, Barca EG, Casanova M, de la Fuente A, Marín-Niebla A, Muntañola A. Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2022;40(11):1196.

Dreyling M, Jurczak W, Jerkeman M. IIbrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778.

CAS  Article  Google Scholar 

Karmali R, Abramson JS, Stephens DM, Barnes JA, Kaplan J, Winter JN, et al. Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease. Blood. 2020;136(Supplement 1):30–1.

Article  Google Scholar 

Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799–803.

CAS  Article  Google Scholar 

Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109–16.

Article  Google Scholar 

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

CAS  Article  Google Scholar 

Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Shibayama H, et al. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Cancer Sci. 2016;107(12):1785–90.

CAS  Article  Google Scholar 

Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(11):1449–58.

CAS  Article  Google Scholar 

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4(1):e15–23.

Article  Google Scholar 

Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial. J Clin Oncol: the official journal of the American Society of Clinical Oncology. 2020;38(3):248–56.

Article  Google Scholar 

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood, The Journal of the American Society of Hematology. 2018;132(19):2016–25.

CAS  Google Scholar 

Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56.

CAS  Article  Google Scholar 

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–23.

CAS  Article  Google Scholar 

Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–8.

CAS  Article  Google Scholar